Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 805 
ORIGINAL ARTICLE
Year : 2020  |  Volume : 26  |  Issue : 6  |  Page : 312-320

Clinical features of Epstein–Barr virus in the intestinal mucosa and blood of patients with inflammatory bowel disease


1 Department of Geriatrics Medicine and the Center of Inflammatory Bowel Disease, Sichuan University, Chengdu, Sichuan, China
2 Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
3 Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, China
4 Department of Otolaryngology, West China Hospital, Sichuan University, Chengdu, Sichuan, China

Correspondence Address:
Dr. Yu-Fang Wang
Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu-61004, Sichuan
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/sjg.SJG_30_20

Rights and Permissions

Background: The role of Epstein–Barr virus (EBV) in inflammatory bowel disease (IBD) remains to be elucidated. The aim of this study was to investigate the presence of EBV in the blood and intestinal mucosa of patients with IBD and evaluate the association between EBV positivity and IBD. Methods: Patients with IBD, hospitalized between January 2015 and April 2018, were enrolled. The EBV-DNA load in blood samples from each subject was analyzed by quantitative real-time polymerase chain reaction. EBV-encoded small-RNA 1 (EBER-1) was detected by in-situ hybridization in intestinal mucosa tissue sections of patients with IBD. Result: EBV-DNA was detected in 48 out of 568 patients with IBD (8.4%), and EBER-1 positivity was detected in 27 of these patients (56.3%). Refractory IBD and severe mucosal inflammation were more common in patients with detectable levels of EBER-1 than in those without; the number of EBER-1-positive cells positively correlated with mucosal inflammation (P value < 0.05). Age (≥60 years old) and use of azathioprine were risk factors for EBV infection. There was no significant difference in clinical remission rate and surgical rate between the EBER-1 positive group and EBER-1 negative group, antiviral group and the non-antiviral group, among IBD patients who tested positive for EBV-DNA. Conclusion: Elderly patients with IBD, treated with azathioprine, are more susceptible to EBV positivity. Further, EBV mucosal detection correlated with the severity of mucosal damage and refractoriness, but not prognosis.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed743    
    Printed29    
    Emailed0    
    PDF Downloaded84    
    Comments [Add]    

Recommend this journal